Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 8/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1402948 | 0.97 | HSD11B1 (0.59) | HSD11B1L3MBTL1HSD17B10EPHX2NPC1 | |
| SCHEMBL19798424 | 0.76 | KMT2A (0.58) | HSD11B1L3MBTL1HSD17B10EPHX2NPC1 | |
| SCHEMBL15224285 | 0.74 | L3MBTL1 (0.59) | HSD11B1L3MBTL1HSD17B10EPHX2ALDH1A1 | |
| SCHEMBL1016262 | 0.74 | L3MBTL1 (0.65) | HSD11B1L3MBTL1HSD17B10EPHX2EPHX1 | |
| SCHEMBL19808153 | 0.74 | L3MBTL1 (0.63) | HSD11B1L3MBTL1HSD17B10EPHX2ALDH1A1 | |
| SCHEMBL2047350 | 0.72 | HSD11B1 (0.53) | HSD11B1L3MBTL1HSD17B10EPHX2NPC1 | |
| SCHEMBL12968364 | 0.72 | L3MBTL1 (0.72) | HSD11B1L3MBTL1HSD17B10EPHX2ALDH1A1 | |
| SCHEMBL4005434 | 0.72 | L3MBTL1 (0.61) | HSD11B1L3MBTL1HSD17B10EPHX2ALDH1A1 | |
| SCHEMBL11364035 | 0.72 | EPHX1 (0.57) | EPHX2NPC1EPHX1KMT2AALDH1A1 | |
| SCHEMBL4229104 | 0.72 | L3MBTL1 (0.61) | HSD11B1L3MBTL1HSD17B10EPHX2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344016-B2 | Pyrazole derivatives as 11-beta-HSD1 inhibitors | ASTRAZENECA AB (SE) | 2013-01-01 | — | — | US | disclosed |
| US-8344016-B2 | Pyrazole derivatives as 11-beta-HSD1 inhibitors | ASTRAZENECA AB (SE) | 2013-01-01 | — | — | US | disclosed |
| US-8344016-B2 | Pyrazole derivatives as 11-beta-HSD1 inhibitors | ASTRAZENECA AB (SE) | 2013-01-01 | — | — | US | disclosed |
| CN-101668524-B | Pyrazole derivatives as 11-beta-HSD 1 inhibitors | ASTRAZENECA AB | 2012-10-24 | — | — | CN | disclosed |
| CN-102503891-A | Pyrazole derivatives as 11-beta-hsd1 inhibitors | ASTRAZENECA AB | 2012-06-20 | — | — | CN | disclosed |
| US-20110224273-A1 | Pyrazole Derivatives as 11-Beta-HSD1 Inhibitors | ASTRAZENECA AB (SE) | 2011-09-15 | — | — | US | disclosed |
| US-20110224273-A1 | Pyrazole Derivatives as 11-Beta-HSD1 Inhibitors | ASTRAZENECA AB (SE) | 2011-09-15 | — | — | US | disclosed |
| US-20110224273-A1 | Pyrazole Derivatives as 11-Beta-HSD1 Inhibitors | ASTRAZENECA AB (SE) | 2011-09-15 | — | — | US | disclosed |
| EP-2292228-A1 | Pyrazole derivatives as 11-beta-HSD1 inhibitors | AstraZeneca AB (Publ) (SE) | 2011-03-09 | — | — | EP | disclosed |
| US-7816391-B2 | 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid; hydroxysteroid reductase inhibitors; hydrolysis; metabolic syndromes | ASTRAZENECA AB (SE) | 2010-10-19 | — | — | US | disclosed |
| US-7816391-B2 | 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid; hydroxysteroid reductase inhibitors; hydrolysis; metabolic syndromes | ASTRAZENECA AB (SE) | 2010-10-19 | — | — | US | disclosed |
| CN-101668524-A | Pyrazole derivatives as 11-beta-HSD 1 inhibitors | ASTRAZENECA AB | 2010-03-10 | — | — | CN | disclosed |
| EP-2124937-A1 | PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | AstraZeneca AB (SE) | 2009-12-02 | — | — | EP | disclosed |
| US-20090221663-A1 | PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| US-20090221663-A1 | PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| WO-2008099145-A1 | PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | WO | disclosed |
| WO-2008099145-A1 | PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224273-A1 | Pyrazole Derivatives as 11-Beta-HSD1 Inhibitors | HSD11B1, HSD3B1, HSD11B2 | HSD11B1 1/4885L3MBTL1 4595/4885HSD17B10 30/4885 |
| US-20090221663-A1 | PYRAZOLE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | HSD11B1, HSD3B1, HSD11B2 | HSD11B1 1/4885L3MBTL1 4595/4885HSD17B10 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.